Neurocrine Bio agrees $57m takeover of UK biotech Diurnal

Neurocrine Biosciences has featured on lists of potential takeover candidates for years, but has now taken the lead on a buyout of UK biotech Diurnal that if consummated will extend its the

Sosei Heptares banks $30m milestone in Neurocrine Bio allian...

Sosei Heptares has taken another of its partnered G protein-coupled receptor (GPCR) programmes into mid-stage clinical trials, earning a $30 million milestone payment from Neurocrine Biosci

ObsEva files uterine fibroid drug in US, chasing AbbVie, Myo...

Swiss biopharma company ObsEva has filed its oral GnRH antagonist linzagolix for the treatment of uterine fibroids in the US, hoping to expand the number of women eligible for this type of

FDA clears Myovant's relugolix for uterine fibroids, setting...

Myovant has chalked up a second approval for its flagship drug relugolix from the FDA, becoming the first once-daily oral drug in the US to treat heavy menstrual bleeding associated with ut

Neurocrine delays US Parkinson's drug launch amid COVID disr...

The FDA has approved Ongentys, an oral Parkinson’s Disease drug from US biotech Neurocrine Biosciences, which can be added to prolong the effects of standard therapy and help prevent “off”

Neurocrine signs $400M-plus deal with Idorsia for epilepsy d...